Diabetes: lipid-lowering therapies for primary prevention of CVD (T2DM and 10% risk)

Indicator

The percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a lipid-lowering therapy.

Resource impact

The previous indicator IND182 was as follows:

The percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a statin (unless there is a contraindication or statin therapy is declined).

Indicator IND274 updates and replaces IND182 and expands the lipid-lowering therapies in the indicator beyond statins.

Atorvastatin 20 mg is recommended as first-line therapy for the primary prevention of cardiovascular disease in adults with type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more. Alternative lipid-lowering therapies may be considered if statins are contraindicated or not tolerated.

This indicator therefore widens the lipid-lowering therapies in the indicator and is not expected to lead to a significant change in clinical practice. Any associated resource impact is therefore unlikely to be significant.